Literature DB >> 16331773

A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II).

Frederick Wolfe1, Kaleb Michaud, Theodore Pincus.   

Abstract

OBJECTIVE: To develop and validate a composite patient self-report disease activity scale for use in clinical practice and in observational studies and clinical trials.
METHODS: A total of 9078 patients with rheumatoid arthritis completed detailed questionnaires that included measure of quality of life in the form of utilities. We evaluated several disease activity scales by measuring their agreement with the utility scales, and also their assessed ability to predict mortality and prescription for anti-tumor necrosis factor therapy.
RESULTS: A composite index composed of a visual analog scale (VAS) for pain, a patient global VAS, and the Health Assessment Questionnaire (HAQ) or the HAQ II formed the Patient Activity Scale (PAS) and PAS-II. These scales performed as well as or better than longer, more complex scales.
CONCLUSION: A simple, useful clinical scale, the PAS or PAS-II, can be formed by the use of common clinical variables. It is well correlated with and relevant to a wide range of clinical variables. This scale should be useful for comparative studies, clinical care, and regulatory documentation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16331773

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  30 in total

1.  Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patients.

Authors:  Kaleb Michaud; Gene Wallenstein; Frederick Wolfe
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-11-15       Impact factor: 4.794

2.  Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent?

Authors:  Nasim Ahmed Khan; Horace Jack Spencer; Essam Ahmed Abda; Rieke Alten; Christof Pohl; Codrina Ancuta; Massimiliano Cazzato; Pál Géher; Laure Gossec; Dan Henrohn; Merete Lund Hetland; Nevsun Inanc; Johannes Wg Jacobs; Eduardo Kerzberg; Maria Majdan; Omondi Oyoo; Ruben A Peredo-Wende; Zahraa Ibrahim Selim; Fotini Nikolaos Skopouli; Alberto Sulli; Kim Hørslev-Petersen; Peter C Taylor; Tuulikki Sokka
Journal:  Ann Rheum Dis       Date:  2012-04-24       Impact factor: 19.103

3.  Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria.

Authors:  Shadi H Shahouri; Kaleb Michaud; Ted R Mikuls; Liron Caplan; Timothy S Shaver; James D Anderson; David N Weidensaul; Ruth E Busch; Shirley Wang; Frederick Wolfe
Journal:  Arthritis Rheum       Date:  2011-11

Review 4.  Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.

Authors:  Jaclyn Anderson; Liron Caplan; Jinoos Yazdany; Mark L Robbins; Tuhina Neogi; Kaleb Michaud; Kenneth G Saag; James R O'Dell; Salahuddin Kazi
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

Review 5.  2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Authors:  Jasvinder A Singh; Daniel E Furst; Aseem Bharat; Jeffrey R Curtis; Arthur F Kavanaugh; Joel M Kremer; Larry W Moreland; James O'Dell; Kevin L Winthrop; Timothy Beukelman; S Louis Bridges; W Winn Chatham; Harold E Paulus; Maria Suarez-Almazor; Claire Bombardier; Maxime Dougados; Dinesh Khanna; Charles M King; Amye L Leong; Eric L Matteson; John T Schousboe; Eileen Moynihan; Karen S Kolba; Archana Jain; Elizabeth R Volkmann; Harsh Agrawal; Sangmee Bae; Amy S Mudano; Nivedita M Patkar; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

6.  Changes in Alcohol Use and Associations With Disease Activity, Health Status, and Mortality in Rheumatoid Arthritis.

Authors:  Joshua F Baker; Bryant R England; Ted R Mikuls; Jesse Y Hsu; Michael D George; Sofia Pedro; Harlan Sayles; Kaleb Michaud
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-02-12       Impact factor: 4.794

Review 7.  Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis.

Authors:  Rayford R June; Nancy J Olsen
Journal:  Expert Opin Biol Ther       Date:  2016-08-08       Impact factor: 4.388

8.  Health-related quality of life in patients with common rheumatic diseases referred to a university clinic.

Authors:  Karin Laas; Risto Roine; Pirjo Räsänen; Harri Sintonen; Marjatta Leirisalo-Repo
Journal:  Rheumatol Int       Date:  2008-08-06       Impact factor: 2.631

9.  Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience.

Authors:  H Singh; V Gupta; S Ray; H Kumar; P Talapatra; M Kaur; S Kumar; S Arya; R Mathur; N Ghangas
Journal:  Clin Rheumatol       Date:  2012-09-15       Impact factor: 2.980

Review 10.  Outcome measures in inflammatory rheumatic diseases.

Authors:  Jaap Fransen; Piet L C M van Riel
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.